Clinical Trials

Numerous clinical trials evaluate diverse pathological conditions, including psoriasis, neuronal ceroid lipofuscinosis, dysmenorrhea, and somatic pain states. Spanning Phase 1, Phase 2, Phase 4, and unassigned phases, these studies are sponsored by academic centers like Washington University School of Medicine and the University of Oxford alongside commercial entities such as Almirall, S.A. and Spark Biomedical Inc. Operational statuses reflect a broad spectrum across these therapeutic areas, encompassing completed, recruiting, and upcoming trials.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06978036 NOT_YET_RECRUITING
Periodontitis; Periodontal Regeneration, Clinical and Radiographic Results, Modified Minimal Invasive Surgery; Periodontal Regeneration
The University of Hong Kong
 2026-01-02
NCT05654012 RECRUITING
Migraine
Washington University School of Medicine
 2023-06-01
NCT07550686 RECRUITING
Radiotherapy; Patient Education
Yonsei University
 2025-12-01
NCT06335862 ENROLLING_BY_INVITATION
Oesophageal Atresia With Tracheo-Oesophageal Fistula; Tracheomalacia; Oesophageal Atresia
UMC Utrecht
 2024-09-01
NCT07706998 NOT_YET_RECRUITING
Learning
Nanjing University
 2026-07-01
NCT06569615 RECRUITING
Sacroilitis
Najran University
 2024-08-27
NCT05738213 ACTIVE_NOT_RECRUITING
Migraine
Washington University School of Medicine
 2023-01-10
NCT06390267 Not yet recruiting
Acute Stress Reaction|Cognitive Performance
Spark Biomedical Inc.|Battelle Memorial Institute
 2024-08 Not Applicable
NCT05145595 COMPLETED
Pain
Washington University School of Medicine
 2022-09-20
NCT06398574 Recruiting
Shoulder Pain
University of Alcala
 2024-05-06 Not Applicable
NCT06353789 Not yet recruiting
Dysmenorrhea
University of Oxford|University of Exeter|University of York|Endometriosis UK
 2024-05-01 --
NCT05513079 UNKNOWN
Chronic Urticaria; Anxiety
TC Erciyes University
 2022-09
NCT04850950 UNKNOWN
Chronic Hepatitis B; Mother-to-Child Transmission; Safety; Efficacy; Hepatitis B Virus; Tenofovir Alafenamide Fumarate
The First Affiliated Hospital of Zhengzhou University
 2021-04-26 PHASE4
NCT03492021 COMPLETED
Rehabilitative Nutrition for Muscle Recovery From ACL Reconstruction
University of Connecticut
 2018-02-01
NCT03644810 COMPLETED
Catastrophizing Pain; Pain, Somatic; Chronic Low Back Pain
Aalborg University
 2017-05-01
NCT02449356 COMPLETED
Mechanical Ventilation Complication
Wangyuan Zou
 2015-09
NCT01462643 COMPLETED
Psoriasis
Almirall, S.A.
 2011-08 PHASE2
NCT00337636 COMPLETED
Neuronal Ceroid Lipofuscinosis
StemCells, Inc.
 2006-05 PHASE1
NCT00126113 COMPLETED
Hearing Impairment
US Department of Veterans Affairs
 2005-08

(data from https://clinicaltrials.gov, updated on 2025-05-18)

Check the Propyl pyrazole triol (PPT) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Propyl pyrazole triol selectively binds to estrogen receptor alpha, inducing receptor activation and downstream gene transcription that regulates target cell proliferation and differentiation. This ligand-driven signaling alters cellular gene expression profiles and tissue responses, underlying its potential therapeutic relevance in clinical trial settings evaluating inflammatory conditions like psoriasis and pain modulation.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.